Hepatocyte-Targeted Delivery of siRNA Polyplex with PEG-Modified Lactosylated Dendrimer/Cyclodextrin Conjugates for Transthyretin-Related Amyloidosis Therapy
Authors:
- 1 October 2019
- journal article
- research article
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 42 (10) , 1679-1688
Abstract
Targeted drug delivery system (DDS) is required for RNA interference (RNAi) therapy to increase the therapeutic effect and to reduce the adverse effect. Especially in transthyretin (TTR)-related amyloidosis, hepatocyte specific delivery is desired because TTR mainly expresses in hepatocyte. Herein, we report on a hepatocyte-specific small interfering RNA (siRNA) delivery system using polyethylene glycol (PEG)-modified lactosylated dendrimer (generation 3; G3) conjugates with α-cyclodextrin (PEG-LαCs (G3)) for TTR-related amyloidosis therapy, and investigated the in vitro and in vivo gene silencing effect of PEG-LαCs (G3)/siRNA polyplexes. PEG-LαC (G3, average degree of substitution of PEG (DSP) 2)/TTR siRNA (siTTR) polyplex exhibited the asialoglycoprotein receptor (ASGPR)-mediated cellular uptake, high endosomal escaping ability and localization of the siRNA in cytoplasm, resulting in significant TTR silencing in HepG2 cells. In vivo studies showed that PEG-LαC (G3, DSP2)/siTTR polyplex led to a significant TTR silencing effect in liver after systemic administration to mice. Furthermore, safety evaluation revealed that PEG-LαC (G3, DSP2)/siTTR polyplex had no significant toxicity both in vitro and in vivo. These findings suggest the utility of PEG-LαC (G3, DSP2) as a promising hepatocyte-specific siRNA delivery system both in vitro and in vivo, and as a therapeutic approach for TTR-related amyloidosis.Keywords
This publication has 32 references indexed in Scilit:
- Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisNew England Journal of Medicine, 2013
- Design and evaluation of polyamidoamine dendrimer conjugate with PEG,α-cyclodextrin and lactose as a novel hepatocyte-selective gene carrierin vitroandin vivoJournal of Drug Targeting, 2013
- The rough endoplasmatic reticulum is a central nucleation site of siRNA‐mediated RNA silencingThe EMBO Journal, 2013
- Guideline of transthyretin-related hereditary amyloidosis for cliniciansOrphanet Journal of Rare Diseases, 2013
- Recent Findings Concerning PAMAM Dendrimer Conjugates with Cyclodextrins as Carriers of DNA and RNASensors, 2009
- Strategies for silencing human disease using RNA interferenceNature Reviews Genetics, 2007
- Visualizing a Correlation between siRNA Localization, Cellular Uptake, and RNAi in Living CellsChemistry & Biology, 2004
- Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapyBritish Journal of Haematology, 2003
- Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A proteinThe Lancet, 2001
- Molecular dynamics simulations of asialoglycoprotein receptor ligandsBiochemistry, 1993